Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer:pericarcinomatous tissues or peripheral blood lymphocytes?

作     者：Yaxiong Zhang Lianpeng Chang Wenfeng Fang Yunpeng Yang Lanjun Zhang Shaodong Hong Huaqiang Zhou Yanfang Guan Xin Yi Li Zhang 

作者机构：State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhou 510060GuangdongP.R.China Department of Medical OncologySun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhou 510060GuangdongP.R.China Geneplus-Beijing InstituteBeijing 100000P.R.China Department of Thoracic SurgerySun Yat-sen University Cancer CenterGuangzhou 510060GuangdongP.R.China 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2019年第39卷第1期

页      面：314-317页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the National Key R&D Program of China(Grant No.2016YFC0905500,2016YFC0905503) Science and Technology Program of Guangdong(Grant No.2017B020227001,2016A020215084) Science and Technology Program of Guangzhou(Grant No.201607020031,201400000001-2) Chinese National Natural Science Foundation Project(Grant No.81772476,81572659,81602011) Pearl River Nova Program of Guangzhou(Grant No.201610010048) National Natural Science Funds for Young Scholars of China(Grant No.81502355) 

主　　题：lymphocytes lung filtering 

摘      要：Dear editor,Lung cancer is the leading cause of cancer-related death worldwide,with the predominant pathological type being non-small cell lung cancer(NSCLC)[1,2].Next-gener-ation sequencing(NGS)analysis is increasingly used to help clinicians select appropriate target therapies,such as epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)for EGFR-mutant patients[3].Both pericarcinomatous tissues and peripheral blood lymphocytes are widely used as normal control for NGS ***,whether pericarcinomatous tissue is suitable for background filtering in mutation analysis remains *** to the whole-genome sequencing data from The Cancer Genome Atlas(TCGA)database,there were some genomic variations in peri-carcinomatous tissue from NSCLC patients,but no driver gene mutation was detected[4,5].Therefore,deep sequencing of pericarcinomatous and tumor tissues is necessary to confirm whether pericarcinomatous tissue harbors low-frequency mutations.